Advaxis, Inc. (NASDAQ:ADXS) reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $0.39 and last traded at $0.39, with a volume of 4862 shares. The stock had previously closed at $0.41.
ADXS has been the topic of several research analyst reports. HC Wainwright reiterated a “buy” rating on shares of Advaxis in a report on Wednesday, September 12th. ValuEngine upgraded Advaxis from a “hold” rating to a “buy” rating in a report on Thursday, November 1st.
The firm has a market capitalization of $20.82 million, a price-to-earnings ratio of -0.16 and a beta of 2.46.
Advaxis (NASDAQ:ADXS) last issued its earnings results on Monday, September 10th. The biotechnology company reported ($0.27) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.02). The company had revenue of $1.13 million for the quarter, compared to analyst estimates of $1.85 million. Advaxis had a negative return on equity of 165.23% and a negative net margin of 1,062.68%. On average, equities analysts forecast that Advaxis, Inc. will post -1.09 earnings per share for the current fiscal year.
In related news, Director Roni Appel bought 33,333 shares of the stock in a transaction dated Tuesday, September 11th. The shares were acquired at an average cost of $1.20 per share, for a total transaction of $39,999.60. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 7.21% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in ADXS. LMR Partners LLP purchased a new stake in shares of Advaxis during the 2nd quarter valued at approximately $171,000. Paloma Partners Management Co purchased a new stake in shares of Advaxis during the 2nd quarter valued at approximately $265,000. Finally, Renaissance Technologies LLC raised its position in shares of Advaxis by 173.0% during the 3rd quarter. Renaissance Technologies LLC now owns 1,191,846 shares of the biotechnology company’s stock valued at $1,120,000 after buying an additional 755,352 shares during the period. 24.81% of the stock is currently owned by hedge funds and other institutional investors.
About Advaxis (NASDAQ:ADXS)
Advaxis, Inc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based immunotherapies in the United States. It is developing Axalimogene filolisbac and ADXS-Dual that are Lm-LLO immunotherapy product candidates for the treatment of human papilloma virus associated cancers, including cervical, and head and neck cancers.
Featured Article: How to invest in a bear market
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.